Biologics Global Market Opportunities And Strategies To 2021
NEW YORK, August 14, 2018 /PRNewswire/ -- Biologics Global Market Opportunities And Strategies By Product Type: Monoclonal Antibodies (mAbs), Therapeutic Proteins and Vaccines; By Region, By Country, With Forecast Until 2021
Read the full report: https://www.reportlinker.com/p05482361
The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes.Biologics products include a wide range of recombinant therapeutic proteins, vaccines, and monoclonal antibodies.
These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.
Executive Summary
The global biologics market was worth $221 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines. Biologics are very large complex molecules manufactured in a living system such as microorganisms, animal cells or plant cells. They are produced using the recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances. In 2017, 12 biologics were approved in the USA, 10 in European Union and 7 in Japan. There are over 1000 biologics under development which will drive the biologics market in the future. Cancer is the therapeutic area with maximum number of biologics under development and Alzheimer's has the least number.
Of the total biologics market across the globe, Monoclonal antibodies (mAbs) accounted for a share of 43% in 2017 and was worth $94 billion. North America had the highest share in 2017 at $39.2 billion followed by Western Europe with a market value of $26.4 billion. Asia-Pacific was the third largest market with a share of 12% and a market value of $11.4 billion. mAbs are biological drugs that recognize and bind to a specific antigen that causes various chronic health conditions such as arthritis, cancer, multiple sclerosis. mAbs can be further segmented based on the presence of different amounts of murine (mouse or rat origin) sequences in the variable region. The segments consist of murine mAbs, chimeric mAbs, human and humanized mAbs. Of these, humanized mAbs accounted for 43% share in the monoclonal antibody market with a market value of $37.6 billion followed by human mAbs and chimeric mAbs at $32.9 billion and $18.8 billion respectively. Murine mAbs accounted only for 5% of the total mAbs market and was worth $4.7 billion in 2017.
Therapeutic proteins or recombinant proteins are engineered in the laboratory and works by targeting therapeutic process which compensates for the deficiency of an essential protein. Therapeutic proteins include cytokines, peptide hormones and enzymes. The market for therapeutic protein was worth $80 billion in 2017 accounting for a share of 36% of the global biologics market. North American market for therapeutic proteins was worth $33 billion in 2017 followed by Western Europe at $17.3 billion. The market in Asia Pacific was worth $11.3 billion and the markets in South America, Eastern Europe, Middle East and Africa accounted only for 4%, 6%, 9% and 4% respectively. Based on the segmentation of therapeutic proteins into cytokines, peptide hormones and enzymes, peptide hormones accounted for 45% of the market followed by cytokines at 18% and enzymes at 10% share. Other blood factors also had a share of around 27% in the total therapeutic proteins market globally.
Vaccines are biological preparations that stimulate the immune system and prepares it to fight future infections caused by pathogens. Vaccines represented around 21% of the global biologics market and was worth $47 billion in 2017. Vaccines are used for prophylactic (preventive) or therapeutic purposes and the market is segmented based on the end users, children and adults. Pediatric vaccines had the major share of 55% and was worth $26 billion globally. Adult vaccines accounted for 45% of the total vaccines market with a value of $21 billion in 2017. North America was the largest market for vaccines in 2017 with a value of $15 billion followed by Asia Pacific at $13 billion. Western and Eastern Europe was valued at $7.1 billion and $3.6 billion respectively. South America and Africa had a share of 7% each and Middle East was observed to account for the least share of 3% in 2017.
The number of biosimilars being approved is on the rise and is likely to affect the overall growth of biologics market globally, by expanding the market, but also by reducing average pricing. Currently, the ratio of biosimilars to biologics sold is quite similar in European Union (EU) and the USA (4% biosimilars and 96% biologics). In Japan and India, the proportion of biosimilars is higher in these markets, almost 13-19%, compared to EU and the USA.
Description
Where is the largest and fastest growing market for biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biologics market report from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
• A comparison of the biologics market with macro-economic factors and industry metrics is also covered in the report.
• PESTLE Analysis covers the political, economic, social, technological, legal and environmental factors affecting the biologics market.
• Market segmentations break down market into sub markets, including Monoclonal Antibodies, Therapeutic Proteins, Vaccines
• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
• The report also covers key mergers and acquisitions in the biologics market. Key financial deals which have shaped the market in recent years are identified.
Scope
Markets covered: Monoclonal Antibodies, Therapeutic Proteins, Vaccines
Companies mentioned: Amgen, AbbVie, Johnson & Johnson, Bristol-Meyers Squibb, Pfizer Inc., Eli Lilly and Company, F. Hoffmann- La Roche, Merck & Co., GlaxoSmithKline, Sanofi
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, population, GDP
Data segmentations: Country historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Why this report?
Timely and Critical:
- Revised US FDA regulations for biologic drug development
- Growing applications of biologics in the treatment of complex diseases
- Increasing demand for next generation biologics such as ADCs, bispecifics, fusion proteins, and cell and gene therapy
- Increasing incidence of chronic diseases and advances in bio generics and gene therapy driving the development of therapeutic proteins
Reasons to Purchase
• Outperform competitors using accurate up to date demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
• Create regional and country strategies on the basis of local data and analysis.
• Stay abreast of the latest customer and market research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future developments.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Gain a global perspective on the development of the market.
• Report will be updated with the latest data and delivered to you within 10 working days of order.
Read the full report: https://www.reportlinker.com/p05482361
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article